US4446138A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and composition for reducing weight
Assignee: Emisphere Technologies Inc
•
Filing: 1982-02-10
•
Granted: 1984-05-01
•
Expires: 2002-02-10
Abstract
Abstract A method for reducing weight by the administration of L-Dopa or a stabilized form thereof with or without a decarboxylase inhibitor and Molindone wherein Molindone acts as a potentiator to enhance the weight reducing potency of L-Dopa in warm-blooded animals. The synergistic effect of the combination of L-Dopa and Molindone reduces the required dosage of the two drugs to levels which can be tolerated by higher forms of mammals, whereas individually the dosages required to reduce weight in higher mammals is not easily tolerated and may be toxic or lead to undesirable side effects.
Inventors
- 👤 Howard M. Pack
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 03:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/535; A61P; A61P3/00; A61P3/04
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
42 words
A composition for use in the treatment of obesity comprising L-Dopa, a decarboxylase inhibitor in amounts of between about 6% and about 100% by weight of said L-Dopa, and Molindone in amounts of between 1.0 and 50 weight percent of said L-Dopa.
Claim 2
Dependent Claim
42 words
A composition for use in the treatment of obesity comprising L-Dopa, a decarboxylase inhibitor in amounts of between about 6% and about 100% by weight of said L-Dopa, and Molindone in amounts of between 1.0 and 50 weight percent of said L-Dopa.
Claim 3
Dependent Claim
21 words
A composition in accordance with claim 1 wherein said decarboxylase inhibitor is selected from the group consisting of carbidopa and benzerside.
Claim 4
Independent Claim
76 words
A method for treatment of obese warm-blooded animals comprising concurrently administering L-dopa at a daily level of from about 0.01 milligram to about 1 milligram per gram of body weight and Molindone at a daily level of from about 1.0 to about 50 weight percent of said L-dopa, and a decarboxylase inhibitor at a daily level of from about 6 to about 100 weight percent of said L-dopa, whereby weight loss is effected in the animal.
Claim 5
Independent Claim
76 words
A method for treatment of obese warm-blooded animals comprising concurrently administering L-dopa at a daily level of from about 0.01 milligram to about 1 milligram per gram of body weight and Molindone at a daily level of from about 1.0 to about 50 weight percent of said L-dopa, and a decarboxylase inhibitor at a daily level of from about 6 to about 100 weight percent of said L-dopa, whereby weight loss is effected in the animal.
Claim 6
Dependent Claim
27 words
A method in accordance with claim 3 wherein said warm-blooded animal is human and between about 0.25 and about 4.0 grams of said L-Dopa are administered daily.
Claim 7
Dependent Claim
21 words
A method in accordance with claim 3 wherein said decarboxylase inhibitor is selected from the group consisting of carbidopa and benzerside.
Claim 8
Independent Claim
73 words
A method for treatment of obese warm-blooded animals comprising concurrently administering L-dopa at a daily level of from about 0.01 milligram to about 0.5 milligram per gram of body weight, Molindone at a daily level of from about 1.0 to about 50 weight percent of said L-dopa and carbidopa at a daily level of from about 6 to about 100 weight percent of said L-dopa, whereby weight loss is effected in the animal.
Claim 9
Independent Claim
73 words
A method for treatment of obese warm-blooded animals comprising concurrently administering L-dopa at a daily level of from about 0.01 milligram to about 0.5 milligram per gram of body weight, Molindone at a daily level of from about 1.0 to about 50 weight percent of said L-dopa and carbidopa at a daily level of from about 6 to about 100 weight percent of said L-dopa, whereby weight loss is effected in the animal.
Claim 10
Dependent Claim
27 words
A method in accordance with claim 6 wherein said warm-blooded animal is human and between about 0.25 and about 4.0 grams of said L-dopa are administered daily.
Claim 11
Dependent Claim
40 words
A composition for use in the treatment of obesity comprising L-dopa, carbidopa in amounts of between about 6 and about 100 weight percent of said L-dopa, and Molindone in amounts of between 1.0 and 50 weight percent of said L-dopa.
Claim 12
Dependent Claim
40 words
A composition for use in the treatment of obesity comprising L-dopa, carbidopa in amounts of between about 6 and about 100 weight percent of said L-dopa, and Molindone in amounts of between 1.0 and 50 weight percent of said L-dopa.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-01 | 1987-10-31 | 1988-05-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-01 | 1991-10-31 | 1992-05-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-01 | 1995-10-31 | 1996-05-01 | $7700.00 | Window Closed / Lapsed |